Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study

Inclusion Criteria

• •Must be ≥18 years of age at the time of consent
• •Must be able to provide written informed consent personally or by legally authorized representative
• •Must have 1 of the following histologically confirmed Non-Hodgkin Lymphoma (NHL) subtypes:
• •* Diffuse large B-cell lymphoma (DLBCL), NOS; or DLBCL high-grade lymphoma, not otherwise specified (NOS); or DLBCL high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with DLBCL histology (double/triple-hit lymphoma)
• •* Epstein-Barr virus-positive or composite DLBCL are allowed
• •* Follicular lymphoma (FL)
• •Must have been previously treated with ≥ 1 prior systemic therapy (e.g., chemotherapy, immunotherapy, or chemoimmunotherapy)
• •For first relapsed/refractory (R/R) DLBCL cohort, participant must have confirmed R/R disease within 90 days prior to study enrollment and must intend to initiate 2L systemic treatment
• •For first R/R FL cohort, participant must have confirmed R/R disease (grade 1 to 3B or transformed) within 90 days prior to study enrollment and must intend to initiate 2L systemic treatment
• •Participant must be willing and able to complete enrollment and follow-up health-related quality of life (HRQoL) and social support instruments
• •Participants volunteering for the Tissue Sub-Study must consent for use of their blood/tumor biopsies, which were collected as per standard of care, for exploratory analyses